

**ANTI-INFLAMMATORY POTENTIAL OF JUSTICIA GENANDRUSSA  
BURM F. AND CHARACTERIZATION OF SOME  
PHYTOCONSTITUENT BY GC-MS.**

**Narendra D.Phatangare\*<sup>1</sup>, Dr.K.K.Deshmukh<sup>1</sup>, Dr. V.D.Murade<sup>2</sup>, Dr.D. P. Hase<sup>3</sup>,  
Dr.D.N.Raut<sup>3</sup>**

<sup>1</sup>S.N.Arts, D.J.M. Commerce and B.N.S. Science College, Sangamner, Dist: A.Nagar,  
Maharashtra, India-422605.

<sup>2</sup>Padmashri Vikhe Patil College of Arts, Science and Commerce, Pravaranagar.

<sup>3</sup>Amrutwahini College of Pharmacy, Sangamner.

Article Received on 13/01/2017

Article Revised on 04/02/2017

Article Accepted on 26/02/2017

**\*Corresponding Author**

**Narendra D.Phatangare**

S.N. Arts, D.J.M. Commerce  
and B.N.S. Science College,  
Sangamner, Dist: A.nagar,  
Maharashtra, India-422605

**ABSTRACT**

*Justicia genandrusa* Burm f. is a small tree in *Acanthaceae* family, traditionally used in treatment of several diseases viz., inflammation, diabetes, hypertension, wounds, pain, asthma, rheumatism etc. The present study was carried out to investigate the anti-inflammatory activity of leaves of *Justicia genandrusa* Burm f. The powdered leaves

were successively extracted with petroleum ether and chloroform. The result of the study showed 69.43% inhibition. Acute oral activity of crude extracts shows nil results. The GC-MS study showed the presence of phytoconstituent like, Caryophyllene (2.13%), 5-(7a-isopropenyl-4, 5-dimethyl-octahydroinden-4-yl)-3-methyl-pent-2-enal (1.10%), 13Docosenamide, (Z) (21.86%), Squalene (1.64) etc.

**KEYWORDS:** Anti-inflammatory, rheumatism etc.

**INTRODUCTION**

It is a well-known fact that traditional systems of medicines always played important role in meeting the global health care needs (Ravishankar, 2007). India has the unique distinction of having six recognized systems of medicine and they are Ayurveda, Siddha, Unani, Yoga,

Naturopathy and Homoeopathy. Botanicals are the vital part of these traditional medicines. Although the traditional Indian system of medicine has a long history of use, they required adequate scientific validation (WHO, 1998). Siddha system of medicine is one of the oldest systems of medicine practiced in Akole, India especially in Maharashtra. This *Justicia genandrusa Burn f.* traditionally used for the treatment of Rheumatic arthritis, in old joint pain. The present research work is designed to identify the bioactive compounds which are present in the polyherbal formulation.

## MATERIAL AND METHODS

### Collection and Authentication of Plant material

The botanical species of *Justicia genandrusa Burn f.* was collected from rural areas of Akole tahsil in Ahmednagar district in Maharashtra, India and it was authenticated by Botanical Survey of India (BSI), Pune.

### Preparation of the sample

In house formulation of sample was prepared by leaves were collected and dried under shade for 7 days. After drying, each plant material was finely powdered and sieved (40mesh). After sieving it was stored in airtight container and used for further studies.

### Extraction of leaves

The powdered leaves sample of *Justicia genandrusa Burn f.* was extracted with pet-ether (40:60) by using soxhlet apparatus followed by chloroform until the extraction was completed. After the completion of the extraction, the extract was filtered and the solvent was removed by evaporating on Rota evaporator (Heidolph Laborota 400 efficient). Dark green colour residue was obtained. The percentage yield of the extract was 18.50 %. It was used for anti-inflammatory activity and further GC-MS analysis.

### Gas Chromatography-Mass Spectroscopy (GC-MS) analysis

GC-MS analysis was carried out using GC of make Thermo trace 1300 GC and Ms of make Thermo TSQ 8000. TG 5MS capillary column (30m X 0.25mm, 0.25 $\mu$ m) employing for separation of components and operating in electron impact Ionization mode at 70eV. Helium was used as carrier gas at a constant flow of 1.0 ml/min and an injection volume of 1.0 $\mu$ L was employed. The temperature of Injector and ion source were maintained at 230°C. The oven temperature was programmed from 60°C for 2 min, 280°C for 10 min. Mass spectra were obtained at 70eV. A scan interval is 0.5 seconds and fragments from 40 to 450 Da. The

amount of each component was calculated on relative percentage basis comparing its average peak area to the total areas. The Total Ion Chromatogram (TIC) was created by summing up intensities of all mass spectral peaks. The detector used is MS TSQ 8000.

### **Anti-inflammatory Activity**

#### **1. *In vitro* anti-inflammatory activity by Inhibition of protein denaturation method.**

**Test Solution (0.5 ml):** 0.45 ml of BSA (Bovine serum albumin) (5% w/v aqueous solution) and 0.05 ml of extract solution (250 µg/ml).

**Test Control solution (0.5 ml):** 0.45 ml of BSA (5% w/v aqueous solution) and 0.05 ml of distilled water.

**Standard Control Solution (0.5 ml) :** 0.45 ml of BSA (5% w/v aqueous solution). And 0.05 ml of standard drug (Diclofenac sodium) solution (250 µg/ml). All the above solution were adjusted to pH 6.3 using 1N HCl, The samples were incubated at 37°C for 20 minutes and the temperature was increased to keep the sample at 57°C for 3 minutes. After cooling, 2.5 ml phosphate buffer saline was added to the above solutions. The absorbance was measured using UV spectrophotometer at 416 nm. The percentage inhibition of protein denaturation was calculated as -

$$\% \text{ Inhibition} = [(\text{Ab of Control} - \text{Ab of Test}) / \text{Ab of Control}] \times 100$$

The control represents 100% denaturation. The results compared with Diclofenac sodium (250 µg/ml).


#### **2. *In vivo* anti-inflammatory activity by carrageenan-induced rat paw edema.**

The extract was evaluated for the anti-inflammatory activity. Acute inflammation was produced by sub-plantar injection of 0.1 ml of 1% Carrageenan in normal saline in the right hind paw of the rats, 1h after the administration of the drug/extract. The paw diameter was measured by using digital vernier calipers at the intervals of 1, 3 and 5 hrs after the Carrageenan injection. Indomethacin (10 mg/kg, orally) was used as standard drug and extract administered (100 mg/kg, 200 mg/kg and 400 mg/kg) as test sample. The anti-inflammatory activity was calculated as percentage inhibition of Carrageenan induced paw edema using the following formula.

$$\text{Percent inhibition} = 1 - [(\text{paw diameter in treated} / \text{paw diameter in control}) \times 100].$$

## RESULTS

## GC-MS spectra of pet ether extract



**Figure 1: GC-MS spectra of pet-ether extract.**

About 25 chemical constituent were identified from pet ether extract of *Justicia genandrusa* *Burm f.* using GCMS analysis. The phytoconstituents were identified in pet-ether extracts using GC-MS Analysis. These phytoconstituents were recognize to mass spectrum attach to Gas chromatogram compounds were recognized through mass spectrum attached with Gas chromatogram. The identified phytoconstituent are tabulated in table-1.

**Table 1: Phytoconstituent identified in pet- ether extract of *Justicia genandrusa* *Burm f.***

Sr. No.	Retention Time	Name of phytoconstituents	Molecular Formula	Peak Area
1	8.93	1-Dodecene	C <sub>12</sub> H <sub>24</sub>	2.51
2	11.69	Cyclotetradecane	C <sub>14</sub> H <sub>28</sub>	1.41
3	12.24	Caryophyllene*	C <sub>15</sub> H <sub>24</sub>	2.13
4	14.17	Cetene	C <sub>16</sub> H <sub>32</sub>	1.15
5	14.42	Globulol	C <sub>15</sub> H <sub>26</sub> O	4.41
6	17.34	5-(7a-isopropenyl-4,5-dimethyl-octahydroinden-4-yl)-3-methyl-pent-2-en-1-ol	C <sub>20</sub> H <sub>34</sub> O	5.18
7	17.54	Bicyclo[9.3.1]pentadeca-3,7-dien-12-ol,4,8,12,15,15-pentamethyl	C <sub>20</sub> H <sub>34</sub> O	1.11
8	17.68	5-(7a-isopropenyl-4,5-dimethyl-octahydroinden-4-yl)-3-methyl-pent-2-enal	C <sub>20</sub> H <sub>22</sub> O	2.75
9	18.25	Bicyclo[9.3.1]pentadeca-3,7-dien-12-ol,4,8,12,15,15-pentamethyl	C <sub>20</sub> H <sub>34</sub> O	1.74
10	18.45	Hexadecanoic acid,2-methyl-,methyl ester	C <sub>18</sub> H <sub>36</sub> O <sub>2</sub>	2.08
11	18.53	1-naphthalenepropanol	C <sub>20</sub> H <sub>36</sub> O <sub>2</sub>	1.04
12	18.86	Bicyclo[9.3.1]pentadeca-3,7-dien-12-ol,4,8,12,15,15-pentamethyl	C <sub>20</sub> H <sub>34</sub> O	1.33
13	19.42	5-(7a-isopropenyl-4,5-dimethyl-octahydroinden-4yl)-3-methyl-pent-2-en-1-ol	C <sub>20</sub> H <sub>34</sub> O	1.32
14	19.94	5-(7a-isopropenyl-4,5-dimethyl-octahydroinden-	C <sub>20</sub> H <sub>32</sub> O	0.77

		4yl)-3-methyl-pent-2-enal		
15	20.03	n-propyl 9,12-octadecadecadienoate	C <sub>12</sub> H <sub>38</sub> O <sub>2</sub>	0.76
16	20.10	9,12,15-octadecatrienoic acid, ethyl ester,(Z,Z,Z)	C <sub>20</sub> H <sub>34</sub> O	3.28
17	20.38	5-(7a-isopropenyl-4,5-dimethyl-octahydroinden-4-yl)-3-methyl-pent-2-enal*	C <sub>20</sub> H <sub>32</sub> O	1.10
18	20.86	Cedran -diol,(8S,14)	C <sub>15</sub> H <sub>26</sub> O <sub>2</sub>	1.17
19	21.37	Cedran, 8-propoxy-	C <sub>18</sub> H <sub>32</sub> O	1.45
20	21.69	2-Heptanone	C <sub>13</sub> H <sub>20</sub> O <sub>3</sub>	8.79
21	22.89	7-(acetyloxy)decahydro-2,9,10-trihydroxy-3,6,8,8,10-pentamethyl	C <sub>28</sub> H <sub>40</sub> O <sub>12</sub>	2.55
22	23.54	4(2,2,6 Trimethylbicyclo[4.1.0] (hept1yl) butan 2 one	C <sub>14</sub> H <sub>24</sub> O	3.31
23	23.78	2-Pentenoic acid	C <sub>20</sub> H <sub>32</sub> O <sub>2</sub>	5.12
24	24.40	4(2,2,6Trimethylbicyclo[4.1.0](hept1yl)butan-2 -one	C <sub>14</sub> H <sub>24</sub> O	1.59
25	24.59	2 Pentanoic acid	C <sub>20</sub> H <sub>32</sub> O <sub>2</sub>	4.60
26	25.15	13Docosenamide,(Z)*	C <sub>22</sub> H <sub>43</sub> NO	21.86
27	25.53	Squalene*	C <sub>30</sub> H <sub>50</sub>	1.64
28	26.16	Tetratetracontane	C <sub>44</sub> H <sub>90</sub>	2.80
29	28.71	Triacontane	C <sub>30</sub> H <sub>62</sub>	7.28
30	32.50	Tetracosane 32.50	C <sub>24</sub> H <sub>50</sub>	3.76

The nature and structure of the compounds were identified at different time intervals using mass spectrometer. The heights of the different peaks indicate the relative concentration of the different components present in the sample. The finger prints of the compound which can be identified from The National Institute of Standard and Technology (NIST) library database.

#### Acute oral toxicity study

**Table 2: indicates that the pet-ether extract is non- toxic for further use.**

Sr. No.	Dose (mg/kg)	Leathality		
		P <sub>1</sub>	P <sub>2</sub>	P <sub>3</sub>
1	5 mg/kg	0/3	0/3	0/3
2	5 mg/kg	0/3	0/3	0/3
3	50 mg/kg	0/3	0/3	0/3
4	50 mg/kg	0/3	0/3	0/3
5	300 mg/kg	0/3	0/3	0/3
6	300 mg/kg	0/3	0/3	0/3
7	2000 mg/kg	0/3	0/3	0/3
8	2000 mg/kg	0/3	0/3	0/3

**Anti-inflammatory activity****Table 3: *In-vivo* anti-inflammatory activity by using Caragenan induced paw edema**

S. No.	Sample	Concentration	% Inhibition
1.	Diclofenac sodium (Standard)	250 µg/ml	87.25±0.238
2.	P <sub>1</sub> Pet-Ether	250 µg/ml	69.43±0.384
3.	C1 Chloroform	250 µg/ml	16.46±0.332
4.	P <sub>2</sub> Pet-Ether	250 µg/ml	61.47±0.192
5.	C2 Chloroform	250 µg/ml	28.14±0.377
6.	P <sub>3</sub> Pet-Ether	250 µg/ml	76.84±0.316
7.	C3 Chloroform	250 µg/ml	22.91±0.384

**% Inhibition of various extracts**

% Inhibition = (Abs of Control – Abs of Test)/Abs of control

Table-1. Indicate the activity with comparison with Diclofenac sodium (Standard).The pet-ether extract shown strong activity in three samples. It is considered for further study of anti-inflammatory compounds.

**Paw diameter (mm) of sample P<sub>1</sub>.****Table 4: indicates the percentage inhibition of pet- ether extract of *Justicia genandrusa* *Burm f.***

Group	Paw diameter (mm)			% Inhibition
	1hr	3hr	5hr	
Control	2.93±0.134	3.99±0.132	3.41±0.354	--
Standard	0.76±0.042	1.10±0.091	0.57±0.060	83.23
Pet-ether extract(100mg/kg)	2.72±0.022	3.69±0.044	2.60±0.019	23.52
Pet-ether extract(200mg/kg)	2.45±0.013	3.09±0.016	2.11±0.019	37.94
Pet-ether extract(400mg/kg)	1.58±0.134	2.44±0.036	1.28±0.109	62.64

**DISCUSSION****Identification of compounds**

The compounds were identified by interpretation of the spectrum of the unknown compounds with the spectrum of the known compounds mentioned in The National Institute of Standard and Technology (NIST) library database.

**Anti-inflammatory activity**

The present results indicate that pet-ether and chloroform extracts of *Justicia genandrusa* *Burm f.* have anti-inflammatory activity on animal by paw edema model. The both extracts

showed activity against acute and chronic inflammation. The pet ether and chloroform extract showed anti-inflammatory activity in the chronic inflammatory test.

## CONCLUSION

1. The extraction protocols developed coupled with GC–MS used in this study allowed us to analyze target compounds at concentrations of nanograms per gram with a high sensitivity and selectivity. Our results showed that pet-ether and Chloroform extracts were effective in the extraction of Anti-inflammatory compounds. Considering the hazards of solvent volume and toxicity associated which shows.

2. It can be concluded that the pet-ether and chloroform extract of leaves of *Justicia genandrussa* *Burm f.* possess anti-inflammatory activity thus validating the ethnopharmacological claims. This knowledge could be tapped to formulate new agents to treat inflammatory and allergic ailments.

## ACKNOWLEDGEMENT

The authors are thankful to Dr.Chavan, Principal, Amrutwahini Pharmacy College, Sangamner for linguistic help in Anti-inflammatory activity. I expressed my gratitude to Dr.K.K.Deshmukh for guiding me for availing laboratory facility during research work.

## REFERENCES

1. Biswakanth Kar, RB Suresh Kumar, Indrajit Karmakar, Narayan Dolai, Asis Bala, Upal K Mazumder, Pallab K Haldar, Antioxidant and in vitro anti-inflammatory activities of *Mimusops elengi* leaves, *Asian Pacific Journal of Tropical Biomedicine* (2012).
2. Seewaboon Sireerata wong, Supaporn Vannasiri, Suphachai Sritiwong, Arun porn Itharat, Kanjana Jaijoy. Anti-Inflammatory, Anti-Nociceptive and Antipyretic Effects of the Ethanol Extract From Root of *Piper Sarmentosum* Roxb., *J Med Assoc Thai*, 2010; 93(7): S1-S6.
3. Anonymous. The Siddha Formulary of India, Ministry of Health and Family Welfare, Department of Health, Govt. of India, (1), 1992.
4. Anonymous. World Health Organization, Quality control methods for medicinal plant materials, Geneva, 1998.
5. Basher M.Rezk *et.al.*The antioxidant activity of Phloretin: The disclosure of a new antioxidant pharmacophore in flavonoids, *Biochemical and Biophysical Research Communications*, 2002; 295: 9-13.

6. Belury MA et.al. Dietary conjugated linoleic acid modulation of phorbol ester skin tumor promotion. *Nutrition and Cancer*, 1996; 26(2): 149-57.
7. Carlos M. Contreras et.al. Anxiolytic-Like Effects in Wistar Rats in the Elevated Plus Maze, *Biomed Research International*, 2014; 4921-41.
8. Elizebeth Thomas et.al. GC-MS Analysis of Phytochemical compounds present in the Rhizomes of *Nervilia aragoana* Gaud, *Asian Journal of Pharmaceutical and Clinical Research*, 2013; 6(3): 68-74.
9. Fukuzawa M et.al. Possible involvement of long chain fatty acids in the spores of *Ganoderma lucidum* (Reishi Houshi) to its anti-tumor activity, *Biological and Pharmaceutical Bulletin*, 2008; 31(10): 1933-7.
10. Hunter JE et.al. Cardiovascular disease risk of dietary stearic acid compared with Trans, other saturated and unsaturated fatty acids: A systematic review, *American Journal of Clinical Nutrition*, 2009; 91(1): 46-63.
11. Karpagasundhari C et.al. Analysis of bioactive compounds in *Physalis minima* leaves using GC-MS, HPLC, UV VIS and FTIR Techniques, *Journal of Pharmacognosy and Phytochemistry*, 2014; 3(4): 196-201.
12. Lember N et.al. Methyl pyruvate initiates membrane depolarization and insulin release by metabolic factors other than ATP, *Biochemistry Journal*, 2001; 354: 345-50.
13. Lim JC et.al. Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer, *Clinical and Experimental Pharmacology and Physiology*, 2012; 39(3): 300-10.
14. Loganathan N et.al. Research Trust Publications, Puducherry, 2007; 1: 365-368.
15. Mensink RP et.al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, *American Journal of Clinical Nutrition*, 2003; 77(5): 1146-1155.
16. Murugesan, Amudha, Shanmugam Rani, GC-MS Analysis of bioactive components of *Cordia retusa*, *Hygeia. Journal of Drugs and Medicines*, 2014; 6(1): 12-19.
17. Nakatsuji T et.al. Antimicrobial Property of Lauric Acid Against *Propionibacterium acnes*: Its Therapeutic Potential for Inflammatory Acne Vulgaris, *The Journal of Investigative Dermatology*, 2009; 129(10): 2480-8.
18. Phillips ML, Bonjouklian R, Cyclic platelet-activating factor analogues derived from 2-deoxy-D-erythro-pentose. *Carbohydrate Research*, 1986; 146: 89-96.
19. Raaman N, Phytochemical techniques, New India Publishing Agency, New Delhi, 2006; 306.



20. Ravishankar B, Shukla VJ, Indian Systems of Medicine: A Brief Profile, *African Journal of Traditional and Complementary Alternative Medicine*, 2007; 4(3): 319-337.
21. Sermakkani M, Thangapandian V, GC-MS Analysis of *Cassia Italica* leaf methanol extract, *Asian Journal of Pharmaceutical and Clinical Research*, 2012; 5(2): 90-94.
22. Teres S et.al. Oleic acid content is responsible for the reduction in blood pressure induced by olive oil, *The National Academy of Sciences* 2008; 105(37): 1381-6.
23. *The National Institute of Standard and Technology* (NIST) library database <http://www.nist.gov/srd/nist1a.cfm>.
24. Yang D et.al. The Antimicrobial Activity of Liposomal Lauric Acids Against *Propionibacterium acnes*, *Biomaterials*, 2009; 30(30): 6035-40.
25. Zawalich WS, Zawalich KC, Influence of pyruvic acid methyl ester on rat pancreatic islets. Effects on insulin secretion, phosphoinositide hydrolysis, and sensitization of the beta cell, *The Journal of Biological Chemistry*, 1997; 272: 3527-31.